Hybrid and decentralized clinical trial models are often discussed in terms of technology: remote visits, telemedicine, wearable devices, home-based assessments, and digital data collection. While these capabilities are important, they only tell part of the [...]
A WEP Clinical White PaperWith Every Patient Executive Summary Cell and gene therapy (CGT) trials operate at the intersection of scientific precision and operational complexity. These programs require highly controlled environments to ensure product integrity, [...]
Neurology is one of the most dynamic and scientifically promising therapeutic areas in clinical research today. With advances in treatments for Alzheimer’s disease, Parkinson’s, multiple sclerosis, ALS, and rare neurodegenerative disorders moving at an unprecedented [...]
Most site activation delays aren’t caused by complexity. They are caused by how we manage the complexity.In a recent article, WEP’s SVP, Head of Global Project Management, Jen Banks, outlined five key strategies to reduce [...]
At last year’s Operationalize Expanded Access Programs Summit, I explored a question that was on many Sponsors’ minds: "What is the value of collecting real world data in EAPs, and how can it support commercial [...]
Bringing clinical trial sites from selection to activation is one of the most time-sensitive and operationally complex phases of study start-up. Delays at this stage ripple across timelines, budgets, and ultimately patient access. Yet, accelerating [...]
Accelerating Vaccine Development Through Community-Based Pharmacy Clinical Infrastructure The partnership between WEP Clinical and RxE2 establishes a differentiated model for vaccine trial execution: one that leverages the accessibility of community pharmacies alongside global clinical [...]
A WEP Clinical White Paper With Every Patient In Recognition of International Childhood Cancer Day - February 15 Executive Summary Scientific innovation in pediatric oncology has accelerated, yet clinical trial participation among children with cancer [...]
A WEP Clinical White PaperWith Every PatientIn Recognition of World Cancer Day – February 4 Executive Summary Each year on World Cancer Day, the global oncology community reflects on both progress made and the work [...]
The FDA’s expectations around equitable access and representative enrollment in clinical research have moved from encouraged to operationally expected. With the FDA’s Enhancing Participation in Clinical Trials - Eligibility Criteria, Enrollment Practices, and Trial Designs final guidance (published December 15, [...]
